Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.70 |
| ▸ | PLK1 | P53350 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | ICMT | O60725 | 1/20 | 0.53 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747715 | 0.88 | CDC25A (0.80) | CDC25APLK1LMNAALDH1A1MCL1 | |
| SCHEMBL2595601 | 0.86 | ICMT (0.71) | CDC25APLK1LMNAALDH1A1NR4A2 | |
| SCHEMBL18180209 | 0.85 | CDC25A (0.63) | CDC25APLK1LMNAALDH1A1MCL1 | |
| SCHEMBL15747729 | 0.85 | CDC25A (0.90) | CDC25APLK1LMNAALDH1A1MCL1 | |
| SCHEMBL9210193 | 0.84 | PLK1 (0.58) | CDC25APLK1LMNAMCL1NR4A2 | |
| SCHEMBL2429439 | 0.84 | CDC25A (0.97) | CDC25APLK1ALDH1A1MCL1ICMT | |
| SCHEMBL28366322 | 0.84 | PLK1 (0.67) | CDC25APLK1LMNAALDH1A1MCL1 | |
| SCHEMBL28365640 | 0.83 | PLK1 (0.67) | CDC25APLK1LMNAALDH1A1MCL1 | |
| SCHEMBL13228230 | 0.83 | NR4A2 (0.61) | CDC25APLK1LMNAALDH1A1NR4A2 | |
| SCHEMBL15747697 | 0.83 | CDC25A (1.00) | CDC25APLK1ALDH1A1MCL1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139459-B2 | Enhancer of fertilization function of sperm | TOHOKU UNIVERSITY (JP) | 2024-11-12 | — | — | US | disclosed |
| US-20220106270-A1 | ENHANCER OF FERTILIZATION FUNCTION OF SPERM | KAKE EDUCATIONAL INSTITUTION (JP) | 2022-04-07 | — | — | US | disclosed |
| CN-110218206-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-110526903-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2021-12-10 | — | — | CN | disclosed |
| US-20210348139-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-11-11 | — | — | US | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-10869858-B2 | Therapeutic agent for amyotrophic disorders | TOHOKU UNIVERSITY (JP) | 2020-12-22 | — | — | US | disclosed |
| US-10869858-B2 | Therapeutic agent for amyotrophic disorders | TOHOKU UNIVERSITY (JP) | 2020-12-22 | — | — | US | disclosed |
| CN-107174581-B | Application of N-alkyl indole compounds in preparation of anti-HIV (human immunodeficiency Virus) medicines | 中国医学科学院药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| US-20130309697-A1 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME | MITCHELL MATTHEW W (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2657705-A2 | Biomarkers for prostate cancer and methods using the same | Metabolon Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013142770-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | CODEXIS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| US-8518650-B2 | Biomarkers for prostate cancer and methods using the same | METABOLON, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2560006-A2 | Biomarkers for prostate cancer and methods using the same | Metabolon Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2061899-B1 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME | METABOLON INC (US) | 2012-08-29 | — | — | EP | disclosed |
| CN-101812097-B | Indole carbazole and bisindole maleimide alkaloid, preparation method and application thereof | OCEAN UNIV CHINA | 2012-04-25 | — | — | CN | disclosed |
| US-20100292331-A1 | Biomarkers for Prostate Cancer and Methods Using the Same | METABALON, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| CN-101812097-A | Indole carbazole and bisindole maleimide alkaloid and its production and application | OCEAN UNIV CHINA | 2010-08-25 | — | — | CN | disclosed |
| US-20070298998-A1 | Biomarkers for amyotrophic lateral sclerosis and methods using the same | METABOLON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139459-B2 | Enhancer of fertilization function of sperm | CATSPER1, NASP, ZP1 | CDC25A 3493/4885PLK1 1054/4885LMNA 3940/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | CDC25A 3942/4885PLK1 3309/4885LMNA 2020/4885 |
| US-20220106270-A1 | ENHANCER OF FERTILIZATION FUNCTION OF SPERM | CATSPER1, NASP, ZP1 | CDC25A 3493/4885PLK1 1054/4885LMNA 3940/4885 |
| US-10869858-B2 | Therapeutic agent for amyotrophic disorders | SMN1; SMN2, MYOF, MUSK | CDC25A 4484/4885PLK1 2178/4885LMNA 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.